$CAI Income Statement | Understand Stock

$CAI

$32.46 +$0.45 (1.42%) Close

$CAI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of operations and comprehensive loss

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025
Revenue
Cost of services - Molecular profiling services
Cost of services - Pharma research and development services
Total revenue
Costs and operating expenses:
Cost of services
Cost of services - Molecular profiling services
Cost of services - Pharma research and development services
Selling and marketing expense
General and administrative expense (see note 11)
Research and development expense
Total costs and operating expenses
Income (Loss) from operations
Other expense, net:
Interest income
Interest expense
Changes in fair value of financial instruments
Other expense, net
Total other expense, net
Loss before income taxes and provision for income taxes
Provision for income taxes
Net loss
Deemed dividend from Series D redeemable convertible preferred stock (see note 6)
Adjustments of redeemable convertible preferred stock to redemption value
Net loss attributable to common shareholders basic
Net loss attributable to common shareholders diluted
Net income (loss) per share attributable to common shareholders:
Net loss per share attributable to common shareholders, basic (in dollars per share)
Net loss per share attributable to common shareholders, diluted (in dollars per share)
Weighted-average shares used in computing net income (loss) per share attributable to common shareholders:
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic (in shares)
Weighted-average shares used in computing net loss per share attributable to common shareholders, diluted (in shares)
Other comprehensive income (loss), net of tax:
Unrealized gain on available-for-sale securities
Foreign currency translation adjustments
Comprehensive loss

Comments